Efficacy of posaconazole prophylaxis in acute myeloid leukemia and myelodysplastic syndrome patients treated with hypomethylating agents.

Byung Soo KimByung-Hyun LeeMin Ji JeonEun Sang YuDae Sik KimSe Ryeon LeeHwa Jung SungChul Won ChoiYong ParkByung Soo Kim

Published in: Therapeutic advances in hematology (2020)

Thus, in AML and MDS patients receiving HMAs, IFI risk may be high during the early cycles, especially when the underlying disease is not controlled. Posaconazole could represent antifungal prophylaxis in these patients; further studies are needed for its appropriate indications.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
acute myeloid leukemia
prognostic factors
candida albicans